MedTrace Logo

Clinical Study Evaluating the Effect of Losartan

NCT06539806 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-08-06

No results posted yet for this study

Summary

The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion.

Pancreatic cancer (PC) is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States, after lung cancer in 2020.

Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry.

Conditions

Interventions

DRUG

Losartan 50mg Tab

The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Osama Mohamed Hassan, Professor · Clinical Pharmacy Department Faculty of Pharmacy, Tanta University

  • Sahar Mohamed El-Ghobashy, Professor · Clinical Pharmacy Department Faculty of Pharmacy, Tanta University

  • Mohamed Abdel Hamid Mohamed, Professor · Clinical Oncology Faculty of Medicine, Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-20
Primary Completion
2026-08-10
Completion
2026-08-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539806 on ClinicalTrials.gov